Merck Sells Off The End Of Non US Opthamology Assets (US Sold To Akorn In Early 2014)

MundiPharma has acquired the balance of the divested Merck/Schering-Plough legacy Opthamology businesses. Regular readers will recall that Akorn (John Kapoor's company) got itself a great deal on the US version of these assets here, in early 2014.

In any event, here is a bit, from a Healio newsfeed:

. . . .Mundipharma Ophthalmology Products Limited has reached an agreement with Merck to acquire Merck’s glaucoma treatment portfolio in Australia, Canada, Latin America, the Middle East, Africa and New Zealand, the company announced in a press release.

The portfolio includes Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution), Cosopt preservative-free, Saflutan (tafluprost), Timoptic (timolol maleate ophthalmic solution), Timoptic XE, Timoptic preservative-free, Trusopt (dorzolamide hydrochloride ophthalmic solution) and Trusopt preservative-free. . . .

The deal “completes the divestiture of [Merck’s] global ophthalmology business as we continue to sharpen our focus in core markets and therapeutic areas and advance our innovative pipeline,” Muna Bhanji, Merck’s president for hospital and specialty care. . . .

So it goes. Onward. Ever onward. "The Wiz" is up next -- live!